Using Customer Data, 23andMe Plans to Invent its Own Drugs

23andMe, a DNA analysis service company who provides information and tools to individuals to learn more about their DNA has announced its plan to invent its own drugs using customer data. This drastic move will allow 23andMe to capitalize on the economic value its...

Drug Developers Pushing Through Adversity

Centerwatch.com produced an interesting article on the implementation of new strategies to improve drug developer’s access to comparator drugs for clinical testing. The article brings to light the difficulty of obtaining comparator drugs, with the Tufts Center for...

Tufts releases report on causes of drug development failures

On September 10, 2013, the Tufts Center for the Study of Drug Development released a report concerning the leading causes of failures in drug development. Based on a study of products that entered clinical development from 2000 through 2009, the study found that Phase...

Supplementary data research causing unnecessary expenditures

Ken Getz, assistant professor at Tufts Center for the Study of Drug Development (CSDD), reports that oftentimes procedures performed in the last drug development stages are in order to find “supplementary, secondary, tertiary, and exploratory endpoints.”...

ACRO Hopes To Educate Through New YouTube Channel

The Association of Clinical Research Organizations (ACRO) has launched a new YouTube channel to educate the public, media, and policymakers about clinical trials. ACRO believes it has an obligation to keep people informed about clinical trials, “…we have an...